基于生理药代动力学模型评估利福平与利奈唑胺转运体介导的相互作用
本研究开发了利奈唑胺的生理药代动力学(PBPK)模型,并用13项临床研究的36个PK数据验证;结合利福平PBPK模型定量评估ABCB1和ABCG2在两者相互作用中的作用。结果显示标准剂量利福平使利奈唑胺AUC和Cmax比值分别为0.77和0.87,与观察值一致;ABCB1起主要作用,高剂量利福平(20-40 mg/kg/日)对利奈唑胺暴露的影响与标准剂量(10 mg/kg/日)相似。
要点
- 利福平与利奈唑胺的DDI主要由ABCB1介导,ABCG2也有贡献。
- 标准剂量利福平使利奈唑胺AUC比值0.77、Cmax比值0.87。
- 高剂量利福平对利奈唑胺暴露的影响与标准剂量相似。
核心结论
- ABCB1是利福平与利奈唑胺相互作用的主要转运体。
- 高剂量利福平对利奈唑胺血浆暴露的影响与标准剂量利福平相似。
研究设计与样本
- 开发利奈唑胺PBPK模型,并用已发表临床PK数据验证。
- 采用PK-SIM内置利福平PBPK模型作为 perpetrator,纳入ABCB1和ABCG2转运体活性及抑制和诱导动力学参数。
- 利用所建模型预测利福平与利奈唑胺合用时利奈唑胺PK,并用已发表数据验证。
- 基于DDI模型预测稳态下高剂量利福平与利奈唑胺合用时利奈唑胺暴露。
主要发现
- 利奈唑胺PBPK模型对来自13项个体临床研究的36个不同PK臂具有可接受的预测性能。
- PBPK预测标准剂量利福平对利奈唑胺的DDI效应,AUC和Cmax比值分别为0.77和0.87,与观察到的DDI比值吻合良好。
- PBPK模拟表明ABCG2和ABCB1均参与利福平与利奈唑胺的DDI,其中ABCB1起主要作用。
- 利福平日剂量从10 mg/kg增至20-40 mg/kg导致相似的利奈唑胺暴露。
关键数值与推荐
- 标准剂量利福平与利奈唑胺合用时,利奈唑胺AUC比值为0.77,Cmax比值为0.87。
- 利福平日剂量从10 mg/kg增至20-40 mg/kg时,利奈唑胺暴露相似。
临床怎么用
- 临床合用时需关注利福平对利奈唑胺暴露的降低作用,ABCB1是主要介导转运体。
- 高剂量利福平方案下利奈唑胺暴露降低程度与标准剂量相似,剂量调整考量可参考标准剂量情形。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The study aims to develop a physiologically-based pharmacokinetic (PBPK) model to quantitatively evaluate the role of ATP-binding cassette sub-family B member 1 (ABCB1) and ATP-binding cassette super-family G member 2 (ABCG2) in the drug-drug interaction (DDI) between rifampin and linezolid and to predict the impact of high-dose rifampin on linezolid pharmacokinetics (PK). METHODS: We developed a PBPK model of linezolid and verified this using published clinical PK data. The built-in PK-SIM PBPK model for rifampin was used as a perpetrator model, which incorporate ABCB1 and ABCG2 transporter activity, along with inhibition and induction kinetic parameters. Using the developed PBPK models, linezolid PK was predicted when co-administered with rifampin and verified using published data. Based on the developed DDI model, linezolid exposure when co-administered with high-dose rifampin at steady state was predicted. RESULTS: The developed linezolid PBPK model had acceptable predictive performance for 36 different PK arms from 13 individual clinical studies. The PBPK-predicted DDI effect of standard dose rifampin on linezolid, with AUC and Cmax ratios of 0.77 and 0.87, respectively, aligned well with observed DDI ratio. PBPK simulations indicated that both ABCG2 and ABCB1 contributed to the DDI between linezolid and rifampin, with ABCB1 playing the major role in the interaction. Increasing the daily dose of rifampin from 10 mg/kg to 20-40 mg/kg resulted in a similar linezolid exposure. CONCLUSIONS: Our study suggested that ABCB1 is the primary transporter responsible for the interaction between rifampin and linezolid. The DDI effect of high-dose rifampin on linezolid plasma exposure is similar to that of standard-dose rifampin.
引用
- Nguyen HD, Pham VH, Hoglund RM, et al. Assessing transporter-mediated rifampin-linezolid interaction using physiologically-based pharmacokinetic modelling. Br J Clin Pharmacol. 2026. PMID: 41588614. doi:10.1002/bcp.70443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。